Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Moberg Pharma AB ( (SE:MOB) ) has shared an update.
Moberg Pharma held an Extraordinary General Meeting where it was resolved to elect Mona Zhang and Fredrik Blom as new board members, enhancing the company’s focus on financial strategy and business development. The meeting also decided to revoke the previous authorization for issuing shares, reflecting the company’s strong financial position, and maintained the remuneration levels for board members.
More about Moberg Pharma AB
Moberg Pharma AB is a Swedish pharmaceutical company specializing in the commercialization of proprietary innovations, particularly in drug delivery of proven compounds. The company’s flagship product, MOB-015, is a topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries and is sold under the brand name Terclara® in Sweden and Norway. Moberg Pharma aims to become a global market leader in nail fungus treatments and is listed on Nasdaq Stockholm.
Average Trading Volume: 145,036
Current Market Cap: SEK404.4M
For an in-depth examination of MOB stock, go to TipRanks’ Overview page.